120 related articles for article (PubMed ID: 38735053)
1. Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy.
Li JX; Shu N; Zhang YJ; Tong QS; Wang L; Zhang JY; Du JZ
ACS Appl Mater Interfaces; 2024 May; 16(20):25665-25675. PubMed ID: 38735053
[TBL] [Abstract][Full Text] [Related]
2. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
[TBL] [Abstract][Full Text] [Related]
3. Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors.
Anfray C; Varela CF; Ummarino A; Maeda A; Sironi M; Gandoy S; Brea J; Loza MI; León S; Calvo A; Correa J; Fernandez-Megia E; Alonso MJ; Allavena P; Crecente-Campo J; Andón FT
Front Immunol; 2023; 14():1334800. PubMed ID: 38259462
[TBL] [Abstract][Full Text] [Related]
4. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
[TBL] [Abstract][Full Text] [Related]
5. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
[TBL] [Abstract][Full Text] [Related]
6. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
7. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
Anfray C; Mainini F; Digifico E; Maeda A; Sironi M; Erreni M; Anselmo A; Ummarino A; Gandoy S; Expósito F; Redrado M; Serrano D; Calvo A; Martens M; Bravo S; Mantovani A; Allavena P; Andón FT
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531246
[TBL] [Abstract][Full Text] [Related]
8. Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy.
Gong Y; Gao W; Zhang J; Dong X; Zhu D; Ma G
J Nanobiotechnology; 2024 Jun; 22(1):341. PubMed ID: 38890636
[TBL] [Abstract][Full Text] [Related]
9. PEGylated Multistimuli-Responsive Dendritic Prodrug-Based Nanoscale System for Enhanced Anticancer Activity.
Duan Z; Cai H; Zhang H; Chen K; Li N; Xu Z; Gong Q; Luo K
ACS Appl Mater Interfaces; 2018 Oct; 10(42):35770-35783. PubMed ID: 30246536
[TBL] [Abstract][Full Text] [Related]
10. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
Rodell CB; Arlauckas SP; Cuccarese MF; Garris CS; Li R; Ahmed MS; Kohler RH; Pittet MJ; Weissleder R
Nat Biomed Eng; 2018 Aug; 2(8):578-588. PubMed ID: 31015631
[TBL] [Abstract][Full Text] [Related]
11. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
12. Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer.
Yuan H; Gui H; Chen S; Zhu L; Wang C; Jing Q; Lv H; Wan Q; Wang S; Zhou S; Ren X; Nie Y; Li L
Int J Nanomedicine; 2024; 19():3589-3605. PubMed ID: 38645464
[TBL] [Abstract][Full Text] [Related]
13. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy.
Rodell CB; Ahmed MS; Garris CS; Pittet MJ; Weissleder R
Theranostics; 2019; 9(26):8426-8436. PubMed ID: 31879528
[TBL] [Abstract][Full Text] [Related]
14. Laser/GSH-Activatable Oxaliplatin/Phthalocyanine-Based Coordination Polymer Nanoparticles Combining Chemophotodynamic Therapy to Improve Cancer Immunotherapy.
Huang Z; Chen Y; Zhang J; Li W; Shi M; Qiao M; Zhao X; Hu H; Chen D
ACS Appl Mater Interfaces; 2021 Aug; 13(33):39934-39948. PubMed ID: 34396771
[TBL] [Abstract][Full Text] [Related]
15. Development of Toll-like Receptor Agonist-Loaded Nanoparticles as Precision Immunotherapy for Reprogramming Tumor-Associated Macrophages.
Zhang Y; Chen Y; Li J; Zhu X; Liu Y; Wang X; Wang H; Yao Y; Gao Y; Chen Z
ACS Appl Mater Interfaces; 2021 Jun; 13(21):24442-24452. PubMed ID: 34008947
[TBL] [Abstract][Full Text] [Related]
16. Supramolecular Peptide Amphiphile Nanospheres Reprogram Tumor-associated Macrophage to Reshape the Immune Microenvironment for Enhanced Breast Cancer Immunotherapy.
Xiao Q; Huang J; Wang X; Chen Z; Zhang W; Liu F; Li J; Yang Z; Zhan J; Cai Y
Small; 2024 May; 20(21):e2307390. PubMed ID: 38100300
[TBL] [Abstract][Full Text] [Related]
17. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
Wan Z; Sun J; Xu J; Moharil P; Chen J; Xu J; Zhu J; Li J; Huang Y; Xu P; Ma X; Xie W; Lu B; Li S
Acta Biomater; 2019 May; 90():300-313. PubMed ID: 30930305
[TBL] [Abstract][Full Text] [Related]
18. Micelle nanovehicles for co-delivery of Lepidium meyenii Walp. (maca) polysaccharide and chloroquine to tumor-associated macrophages for synergistic cancer immunotherapy.
Yang Y; Guo T; Xu J; Xiong Y; Cui X; Ke Y; Wang C
Int J Biol Macromol; 2021 Oct; 189():577-589. PubMed ID: 34450149
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy.
Sun M; Yao S; Fan L; Fang Z; Miao W; Hu Z; Wang Z
Small; 2022 Mar; 18(9):e2106296. PubMed ID: 34914185
[TBL] [Abstract][Full Text] [Related]
20. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
